A prior cost-effectiveness analysis compared iruplinalkib with alectinib in treating patients with ALK + crizotinib-resistant advanced NSCLC in China from the Chinese healthcare setting (Dai et al., 2024). Here, ALK is linked to non-small cell lung carcinoma.